Three-fold improvement in Pharma R&D productivity with repurposing

In a recent analysis of the economics of pharmaceutical innovation, Grabowski and DiMasi calculated that out-of-pocket costs for a new chemical entity (NCE) were $1.395bn, compared to the costs for a ‘post-approval’ product of $466m. Accordingly, it may be possible to obtain three repurposed medicines for the investment in one new chemical entity. This is…

This content is for Subscriber, 1 Week Member, 1 Month Membership and 1 Year Membership members only.
Log In Register